PCV15 Guidelines Adherence and Hypertension Control in Patients Suffering from Cardiovascular Disease  by Ahmad, N. et al.
PCV10
ANTI-GLYCEMIC MEDICATION TREATMENT PATTERNS AMONG TYPE II
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OBJECTIVES: To evaluate changes in anti-glycemic treatment patterns in patients
newly augmenting statin therapy with niacin extended-release (NERS), relative to
patients initiating alternative lipid regimens. METHODS: An observational cohort
study was conducted using integrated administrative claims and laboratory result
data within the HealthCore Integrated Research Database. T2DM patients aged 18
to 64 initiating statin-augmenting therapy (NERS, ezetimibe (EZES), or fenofi-
brate (FFBS)) or statin monotherapy (SM) between 1/1/2005-11/30/2008 (index
date) were included. Patients with 12 months of pre-index eligibility and 1
laboratory result for hemoglobin A1c (HbA1c) within the 12-month period were
included. The utilization and average daily dose (ADD) of anti-glycemic medica-
tions during the 12-month pre-index and follow-up period were compared be-
tween cohorts. RESULTS: A total of 42,250 patients were identified: 2,041 NERS,
6,915 EZES, 3,095 FFBS, and 30,199 SM. Compared to each cohort, NERS pa-
tients were more likely to be male (P0.0001), and have higher prevalence of pre-
existing ischemic heart conditions (P0.0001). NERS patients had lowest pre-
index total cholesterol (174.3  55.2; P0.0001), HDL-C (37.2  10.1; P0.0001),
second lowest LDL-C (93.7 38.4), and second highest TG (245.3 307.0) prior to the
index date. Among oral anti-glycemic therapies, NERS patients were observed to
have the largest decrease in ADD (mg/day) for biguanides (metformin: -155.9 
788.0; P0.0001), sulfonylureas (glimepiride: -0.1  1.9; P  0.0053; glipizide: -0.8 
20.8; P  .0001), TZD’s (pioglitizone: -0.8  8.2; P  0.0210), and incretin mimetic
agents (exenatide: -0.1 3.5; P 0.0012) from pre-index to follow-up. Furthermore,
NERS patients had the smallest increase in ADD of DPP-4’s (sitagliptin: 0.3 17.6;
P  0.0067). CONCLUSIONS: Despite studies indicating the potential for NER to
antagonize glycemic control among T2DM patients, patients initiating NERS were
observed to have decreased utilization and average daily dose of anti-glycemic
medications, relative to alternative treatment regimens.
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OBJECTIVES: To compare medication treatment and 12-month outcomes of pa-
tients aged75 and 75 years who have acute coronary syndromes (ACS) and who
have undergone percutaneous coronary intervention (PCI). METHODS: Data were
from APTOR, robust, prospective, observational registries from 14 European coun-
tries from 2007-2009. Kaplan-Meier (KM) estimates at 12-months post-PCI were
calculated for cardiovascular (CV) event (unstable angina [UA], non-ST-elevation
myocardial infarction [NSTEMI], STEMI, urgent target vessel revascularization,
acute heart failure, ischemic and hemorrhagic strokes or CV death), bleeding, and
mortality by age. RESULTS: 82% were75 years (N3742, median age: 59) and 18%
were 75 years (N803, median age: 79). Older patients tended to be women (38%
vs. 20%); to weigh 60kg (10% vs. 4%); have more hypertension (72% vs. 54%) and
diabetes (26% vs. 20%); have prior MI (28% vs. 18%) and PCI (22% vs. 17%). For
older/younger patients, respectively, the ACS presentation was 25%/22% for UA,
39%/29% for NSTEMI, and 36%/49% for STEMI; treatment at PCI was 14%/10% for
clopidogrel loading doses 300 mg, 24%/33% for GPIIb/IIIa inhibitors, and 5% /11%
for thrombolytic/fibrinolytic therapy. KM (95% CI) estimates for older and younger
patients, respectively, were: 19.8% (17.0%, 22.6%) vs. 13.4% (12.3%, 14.5%) for CV
event, 3.7% (2.4%, 5.1%) vs. 2.6% (2.1%, 3.1%) for bleeding, and 6.8% (5.0%, 8.5%) vs.
1.5% (1.1%, 1.9%) for mortality. CONCLUSIONS: Older patients tended to receive
GPIIb/IIIa and thrombolytic/fibrinolytic therapy less frequently at PCI, contributing
to comparable bleeding rates. However, the higher post-discharge ischemic event
rates suggest that the risk/benefit ratios in the elderly may need to be considered
more carefully. One strategy might be that, if revascularisation is proposed in older
ACS patients, those at lower bleeding risk be treated more aggressively with potent,
newer peri/postprocedural, antiplatelet/antithrombotic management to balance
the post-PCI outcomes disparity at 12 months.
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DIFFERENCES IN THE WEIGHTED AVERAGE DAILY DOSES OF STATINS IN
EUROPE AND THEIR POTENTIAL IMPACT ON CARDIOVASCULAR OUTCOMES
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OBJECTIVES: Market data indicate that simvastatin and atorvastatin, which will
soon come off patent, are prescribed at non-equipotent doses across Europe. We
sought to estimate the differential effects of this on low-density lipoprotein cho-
lesterol (LDL-C) levels and risk of cardiovascular events. METHODS: Weighted av-
erage daily doses (WADDs) of prescribed simvastatin and atorvastatin in 16 West-
ern European countries were derived from IMS data for 2010. Dose-specific, LDL-C
modifying potencies of the 2 statins were derived from the meta-analysis by Nich-
olls et al (Am J Cardiol, 2010). The relationship between reduction in LDL-C
achieved by statin therapy and impact risk of cardiovascular events was derived
from the meta-regression by the Cholesterol Treatment Trialists’ Collaboration
(Lancet, 2010). This showed that for every 1mmol/L reduction in LDL-C, the relative
risk for a major cardiovascular (coronary and/or stroke) event was 0.78 (95%CI
0.76-0.80). RESULTS: Across the 16 Western European countries, the WADDs for
simvastatin and atorvastatin were 28.2mg and 24.4mg, respectively. The corre-
sponding relative reductions in LDL-C at these doses would be 35.8% and 42.0%.
Assuming a pre-treatment LDL-C of 4.0mml/L, these lipid changes would lead to
relative reductions in the risk of a major cardiovascular event of 31.5% and 37.0%,
respectively. In each of the major markets of France, the The Netherlands, Spain,
the UK and Italy, atorvastatin was prescribed at a higher equivalent dose than
simvastatin. Hence it is likely to confer greater potential population cardiovascular
benefits. CONCLUSIONS: In Western Europe, atorvastatin is prescribed at a higher
equivalent dose than simvastatin. The significant advantages of atorvastatin over
simvastatin in terms of LDL-C and cardiovascular risk reduction will be further
enhanced when acquisition prices for atorvastatin fall after its impending loss of
exclusivity.
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OBJECTIVES: This study estimated the effectiveness of rosuvastatin 20mg (R20)
versus atorvastatin 40mg (A40) and 80mg (A80), and rosuvastatin 40mg (R40) versus
A80 in preventing clinical events in several higher cardiovascular-risk patient pop-
ulations using simulation.METHODS:The Archimedes Model was used to simulate
head-to-head clinical trials in several populations based on 10-year Framingham
risk score (FRS) levels (10, 10-20, 20) and EURO-SCORE (5, 5) to estimate the
occurrence of MACE (comprising MI, stroke, and cardiovascular death). Simulated
patients ages 45–70 with FRS 5% were drawn from the National Health and Nu-
trition Examination Survey. Treatment models were validated using biomarker/
outcomes data from published trials. RESULTS: The patient numbers in each FRS
and EURO-SCORE level population ranged from 9190 to 38,313. R20 reduced MACE
more than A40 or A80 and R40 more than A80 in all scenarios, with higher risk
subgroups showing greater absolute benefit. The 5-year number needed to treat
(NNT) to prevent a MACE event for R40 versus A80 for EURO-SCORE5, and5 were
352 and 154 for 5 years and 154 and 72 for 10 years, respectively. The 5-year relative
risk (RR) of MACE for R20 versus A40 was approximately 0.9, irrespective of baseline
risk. The 5-year RR of MACE for R20 versus A80 ranged from 0.92 to 0.94, and for R40
versus A80 it was 0.88 to 0.90. RR estimates were similar at 10 and 20 years; how-
ever, NNT decreased over time. CONCLUSIONS: The Model estimated that R20
lowers the risk of MACE more than A40 or A80, and R40 further lowers risk com-
pared with A80. The estimated absolute risk reduction with rosuvastatin was
greater with higher baseline risk and over time. While simulation models cannot
replace controlled clinical trials, this study highlights the potential of using rigor-
ous modeling approaches to bridge evidence gaps.
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OBJECTIVES: To compare the relative efficacy and tolerability of amiodarone, so-
talol and dronedarone for the treatment of atrial fibrillation (AF) in Australia using
mixed treatment comparisons (MTC). METHODS: There are limited data directly
comparing the safety and effectiveness of dronedarone with the alternatively used
antiarrhythmic drugs (AADs) in Australia. In the absence of direct comparisons, we
have performed an MTC of networks of trials in order to provide best estimates of
the relative effectiveness and safety of the alternative AADs. This approach was
previously used by Freemantle et al (2011) to compare dronedarone not only with
amiodarone and sotalol, but also with flecainide and propafenone. As flecainide
and propafenone are not widely used in Australia, we chose to exclude them from
the current analysis. Literature in AF involving amiodarone, dronedarone, sotalol
or placebo was searched systematically. The 10 selected trials were combined us-
ing MTC models to provide direct and indirect comparisons in a single analysis.
Randomised trials with at least one month of treatment and at least 3 months
follow up were included. RESULTS: Results are presented versus placebo. Trends
towards increased mortality for sotalol (OR 4.67, 95% CI 1.89 – 11.57) and amioda-
rone (OR 2.92, 95% CI 1.17 - 7.31) were found. Conversely, a trend towards decreased
mortality for dronedarone was found (OR 0.87, 95% CI 0.69 – 1.09). CONCLUSIONS:
Using an MTC approach of the AADs available in the Australian clinical setting, we
have shown that dronedarone is associated with a decrease in the risk of all-cause
mortality, and amiodarone and sotalol are associated with an increase in the risk of
all-cause mortality.
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OBJECTIVES: To evaluate doctors’ adherence to Malaysian Clinical Practice Guide-
lines on management of hypertension (CPG 2008) in patients with cardiovascular
disease, and factors associated with guidelines adherence and hypertension
control. METHODS: This was a cross sectional study conducted at outpatient car-
diology clinic of Penang Hospital. A total of 13 doctors practicing in the clinic were
enrolled in the study. Prescriptions written by each doctor to 25 established hyper-
tensive patients with cardiovascular disease (total 325) were noted on visit 1 along
with patients’ demographic and clinical data. Implicit review of patients’ medical
record was conducted to find acceptable rationale for nonadherence to guidelines.
The prescriptions written were categorized either as adherent or non-adherent to
CPG (2008). Two hundred sixty of the enrolled 320 patients (20 out of 25 patients
enrolled per doctor) were followed for another one visit. Blood pressure readings
noted on visit 2 were related to prescriptions written on visit 1. SPSS 16 was used for
data analysis. RESULTS: One hundred ninety-one (73.5%) patients received guide-
lines compliant pharmacotherapy. CPG compliance had statistically significant
weak negative association with left ventricular hypertrophy (LVH) ( -0.241,
P0.01), and diabetes ( -0.228, P0.01). One hundred fifty-four (59.2 %) patients
were on goal BP. Hypertension control had statistically significant weak positive
association with guidelines adherence (0.175, P0.01), and Angiotensin con-
verting enzyme inhibitors (0.195, P0.01), while weak negative association with
diabetes mellitus (-0.148, P0.017), left ventricular hypertrophy (LVH) (-
0.153, P0.017) and monotherapy (-0.168, P0.01). CONCLUSIONS: Adherence
to guidelines resulted in better hypertension control. Overall prescribing practices
were in fair compliance with guidelines but room for further improvement is still
present. Doctors’ poor adherence to guidelines in patients with diabetes mellitus
and LVH needs further probing and focus in future.
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OBJECTIVES: To evaluate impact of guidelines adherence and factors associated
with hypertension control METHODS: This was a cross sectional study conducted
at Penang Hospital. Twenty-six doctors; 13 from cardiology, 5 from nephrology and
4 from hypertension and diabetic clinics each were enrolled in the study. Prescrip-
tions written by each doctor to 25 established hypertensive patients (total of 650)
were noted on visit 1 along with patients’ demographic and clinical data. Implicit
review of patients’ medical record was conducted to find acceptable rationale for
non adherence to guidelines. The prescriptions written were categorized either as
compliant or non-compliant to Malaysian Clinical Practice Guidelines on manage-
ment of hypertension (CPG 2008). Five hundred and twenty of the enrolled 650
patients (20 out of 25 patients enrolled per doctor) were followed for another one
visit. BP readings noted on visit 2 were related to the prescriptions written on visit
1. SPSS 16 was used for data analysis. RESULTS: Three hundred forty-nine (67.1%)
patients received guidelines compliant pharmacotherapy. Two hundred sixty-five
(51%) patients were on goal BP on visit 2. Hypertension control had statistically
significant weak positive association with CPG adherence (0.14, P0.01), greater
number of antihypertensive drugs (Effect size 0.11, P0.01), cardiovascular dis-
ease (0.127, P0.01) and management of hypertension at cardiology clinic
(0.13, P0.01), while moderate positive association with Angiotensin converting
enzyme inhibitors (0.20, P0.01). Statistically significant weak negative associ-
ation was observed between hypertension control and diabetes mellitus ( -0.17,
P0.01), renal disease ( -0.17, P 0.01), and management of hypertension at
nephrology ( -0.10, P0.02) and diabetic clinics ( -0.14, P0.01).
CONCLUSIONS: Guidelines adherent pharmacotherapy resulted in better hyper-
tension control. Suboptimal BP control in patients with diabetes mellitus, renal
disease and treated at nephrology and diabetic clinics needs focus and further
probing.
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OBJECTIVES: To conduct cost-effectiveness analysis of bosentan and sildenafil
compared with standard therapy (ST, i.e. calcium channel blockers and warfarin) in
treatment of primary pulmonary arterial hypertension (PAH) in Russian
Federation.METHODS:We undertook cost-effectiveness analysis of bosentan (62.5
mg bid during first 4 weeks and 125 mg bid further) and sildenafil (25 mg tid) and
estimated incremental cost-effectiveness ratios (ICER) for each drug vs ST. A cohort
of 20 patients with PAH, functional class (FC) III was simulated in a model. The
patients either received bosentanST, or sildenafilST, or ST only. The number of
patients whose health state improves by one FC was considered a criterion of
efficacy. Costs of hospitalization, standard therapy medications, and investiga-
tional drugs were calculated in the model. Data on clinical efficacy of bosentan,
sildenafil, and ST were extracted from clinical trials. Patient’s treatment scheme
considered in the model was based on the results of peer interview. RESULTS: In
our model treatment with bosentan was the most effective: 9 of 20 patients versus
6 and 2 of 20 patients who had improved by one FC with bosentan, sildenafil and ST,
respectively. Also, the highest overall costs were in the bosentan group: 1,163,948
USD per 20 patients per year. Overall costs in case of sildenafil and standard ther-
apy were 724,520 and 57,969 USD per group per year, respectively. However, com-
parison of bosentan with ST yielded lower ICER than comparison of sildenafil with
ST: 157,997 and 166,638 USD per one patient with improvement by one FC, respec-
tively. Trend in the results remained the same with bosentan price up to 4400 USD
per pack in one-way sensitivity analysis. CONCLUSIONS: The results of this study
suggest that treatment of FC III PAH with bosentan is more preferable than treat-
ment with sildenafil.
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OBJECTIVES: The objective of this study was to compare, by means of an indirect
treatment comparison (ITC), the efficacy and safety of a bivalirudin-based antico-
agulation strategy to heparin monotherapy, in patients with ST-elevation myocar-
dial infarction (STEMI) intended for primary percutaneous coronary intervention
(PPCI). METHODS: A systematic literature review was performed using Embase,
Medline, Medline In-Progress, and the Cochrane Library to identify randomised
controlled trials (RCTs) to build a network of bivalirudin and heparin monotherapy
strategies in STEMI patients using a common reference strategy (heparin with
glycoprotein IIb/IIIa inhibitor (heparinGPI)). Identified data were analysed using
fixed and random effects Bayesian ITC. A base-case analysis was constructed from
intention-to-treat populations in the RCTs. Outcomes (mortality, stroke, MI, isch-
aemic target vessel revascularisation (I-TVR), major adverse cardiovascular events,
TIMI major and minor bleeding) were evaluated at 30-days and 1 year. RESULTS:
Eight RCTs were identified for inclusion in the ITC. At 30-days the bivalirudin-based
strategy was expected to result in fewer deaths (odds ratio [OR]:0.55; credible in-
terval [CrL]:0.32,0.95) compared to a heparin monotherapy, which was sustained at
1-year (OR:0.50; CrL:0.31, 0.79). Other outcomes [stroke (OR:0.88; CrL:0.37, 2.13); MI
(OR:0.79; CrL:0.40, 1.55); I-TVR (OR:0.75; CrL:0.38, 1.46); TIMI-major (OR:0.85; CrL:
0.47, 1.52) and TIMI-minor (OR:0.70; CrL:0.41, 1.18) bleeding] also tended favourably
towards bivalirudin. Consistent with the HORIZONS-AMI trial, when compared to a
heparinGPI-based strategy, a bivalirudin-based strategy resulted in fewer deaths
(30-days: OR:0.65; CrL:0.43, 1.00 and 1 year: OR:0.70; CrL:0.49, 0.97) and post-proce-
dural bleeding events (30-day TIMI-Major: OR:0.59; CrL:0.42, 0.83 and TIMI-minor:
OR:0.61; CrL:0.42, 0.87)), with comparable ischaemic protection. Scenario analyses
of RCT in/exclusion did not influence base-case findings. CONCLUSIONS: For
STEMI patients intended for PPCI, a bivalirudin-based strategy is expected to result
in fewer deaths at 30-days and 1-year, compared to using heparin monotherapy.
Other ischaemic and bleeding outcomes also tended towards improvement with
bivalirudin.
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OBJECTIVES: To evaluate prescription of guidelines recommended Angiotensin
converting enzyme inhibitors (ACE inhibitors) to established diabetic hypertensive
patients, and factors associated with prescription of ACE inhibitors and hyperten-
sion control. METHODS: This was a cross sectional study conducted at Penang
hospital. Prescriptions written to enrolled 250 established diabetic hypertensive
patients were noted on visit 1 along with demographic and clinical data. Implicit
review of the patients’ medical record was conducted to find acceptable rationale
for non prescription of ACE inhibitors. The enrolled patients were followed for
another one visit and their blood pressure (BP) readings noted on visit 2 were
related to prescriptions written on visit 1. Data was analyzed by SPSS 16. RESULTS:
Two hundred twenty five (86%) patients had multiple comorbidities. The most
prevalent comorbidity was cardiovascular disease (55.6%). Two hundred sixteen
patients (86.4%) were on polytherapy. ACE inhibitors were the most commonly
prescribed antihypertensive agents, prescribed to 158 (63.2%) patients followed by
Beta blockers prescribed to 154 (61.6%) patients. Ninety-two (36.8%) patients were
not on ACE inhibitors, among whom only 8 (8.6%) had contraindications to its use,
and 12 (13%) had diabetic nephropathy and were on guidelines recommended
Angiotensin receptor blockers. Chronic kidney disease had statistically significant
weak negative association with prescription of ACE inhibitors (-0.13, P0.03).
One hundred nine (43.6%) patients were on goal BP on visit 2. Hypertension control
had statistically significant moderate positive association with the use of ACE in-
hibitors (0.26, P0.01), and weak positive association with use of Aldosterone
antagonists (0.13, P0.04), polytherapy (0.17, P0.01), cardiovascular disease
(0.13, P0.03) and male gender (0.13, P0.03). CONCLUSIONS: Despite of
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